Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC.

Molecular therapy. Oncology·2026

Same author

Corrigendum to 'Design and <i>in vitro</i> validation of Brome mosaic -virus-like particles for gene delivery and immunomodulation of melanoma' [Mater. Today Bio <b>36</b>, February 2026, 102693, https://doi.org/10.1016/j.mtbio.2025.102693].

Materials today. Bio·2026

Same author

Single-Cell Spatial Atlas of High-Grade Serous Ovarian Cancer Uncovers MHC Class II as a Key Predictor of Spatial Tumor Ecosystems and Clinical Outcomes.

Cancer discovery·2026

Same author

Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response.

Nature communications·2026

Same author

Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy.

Journal for immunotherapy of cancer·2025

Same author

What a model: A newly developed pancreatic murine cell line permissive to adenoviral replication.

Molecular therapy. Oncology·2025

Search research articles

Related Experiment Video

Updated: Jul 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Personalizing Oncolytic Virotherapy.

Firas Hamdan^1,2,3, Manlio Fusciello^1,2,3, Vincenzo Cerullo^1,2,3

¹Laboratory of Immunovirotherapy, Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.

Human Gene Therapy

|September 12, 2023

Summary

Oncolytic viruses show promise for cancer treatment by targeting tumor cells. Enhancing anti-tumor immune responses and personalizing treatments with tumor peptides can improve their effectiveness.

Keywords:

cancer immunotherapies cancer vaccines oncolytic viruses

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Related Experiment Videos

Last Updated: Jul 16, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Area of Science:

Oncology
Virology
Immunotherapy

Background:

Oncolytic viruses are engineered to selectively infect and replicate within cancer cells, offering a targeted therapeutic approach.
While demonstrating safety and tumor-specific killing, oncolytic viruses alone have limitations in achieving complete tumor eradication.
The efficacy of oncolytic viruses is significantly influenced by the induction of anti-tumor immune responses.

Approach:

This review explores strategies to augment oncolytic virus-mediated anti-tumor immunity.
Investigates methods for enhancing the immune system's attack against tumors when using oncolytic viruses.
Discusses the integration of tumor-associated peptides to personalize anti-tumor immune responses.

Key Points:

Oncolytic virus therapy offers targeted cancer cell destruction with a good safety profile.
Complete tumor clearance is often not achieved with oncolytic viruses as a standalone therapy.
Harnessing and enhancing anti-tumor immune responses is crucial for maximizing oncolytic virus efficacy.

Conclusions:

Combining oncolytic viruses with immune-boosting strategies can overcome limitations in tumor clearance.
Personalized approaches, such as incorporating tumor-associated peptides, hold potential for optimizing oncolytic virus therapy.
Further research into combination therapies is essential for advancing oncolytic virotherapy in clinical practice.